A quick and simple solution for obesity and aiding weight loss is something that many people would be very grateful for after unsuccessful attempts through diet and exercise alone. The new medications to aid with weight loss are GLP-1 inhibitors and GIP&GLP-1 inhibitors that reduce the feeling of hunger and aids in levelling out blood glucose, allowing people to eat less and exercise more with less of the issues associated with constantly feeling hungry and giving up on their diet plan.
Although these medications are new for obesity, they have been used for Type 2 Diabetics for a while now and have been very effective in aiding blood glucose control and in reducing their weight in conjunction with a healthy diet and increased exercise. There are other medications available to aid with weight loss such as orlistat which is taken with a fatty meal to prevent the fat being absorbed by your body that can be used instead of or in conjunction with GLP-1 inhibitors and GIP&GLP-1 inhibitors.
It is important to note that GLP-1 Inhibitors and GIP&GLP-1 inhibitors will not be effective alone without reducing the daily calories and without increasing exercise, these medications are to aid healthy lifestyle changes through making you less hungry and therefore reducing your stomach size over time so that these changes can be maintained lifelong after discontinuing the medication.
Eligibility
Patients need to have a BMI of 30 or over to be eligible for the treatment (or 27.5 for some minority ethnic groups or those with other weight-related medical conditions) and be between the ages of 18-74, there are also further restrictions for patients on certain other medications or those with certain other medical conditions or medical history.
About these medications
GLP-1 inhibitors such as WeGovy, Ozempic, Trulicity and GIP&GLP-1 inhibitors such as Mounjaro are administered via subcutaneous injection once a week and typically lead to a weight loss of 10-20% of the start weight lost across 72 weeks alongside healthy diet and exercise. Orlistat typically leads to around 10% weight loss over 6 months alongside healthy diet and exercise. Adverse effects of GLP-1 and GIP&GLP-1 inhibitors can commonly include gastrointestinal upset and more rarely can cause pancreatitis and gall bladder disorders. Orlistat commonly causes gastrointestinal upset but more rarely can cause more serious gastrointestinal and kidney issues.
Where to get these medications from
These medications are prescription only and should only be purchased through an online pharmacy or GP service that is reputable, finding out whether the specific pharmacy or GP service is suitably registered and providing appropriate consultations can be done through looking for the CQC information and also by finding the GPhC registration of the online pharmacy to ensure it is operating legally and is providing medication safely. We have partnered with 
to provide a clinically based weight loss programme. Click here for our introductory discount.
